Aptinyx to Participate in Upcoming Conferences
Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company focused on therapies for brain disorders, announced its participation in two upcoming conferences. CEO Norbert Riedel will join the Pain & Addiction Panel at the 4th Annual Neuroscience Innovation Forum on April 29, 2021. Additionally, the company will hold one-on-one investor meetings at the 7th Annual Truist Securities Life Sciences Summit on May 4-5, 2021. Aptinyx is developing novel NMDA receptor modulators targeting conditions like chronic pain and cognitive impairment.
- None.
- None.
Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced that the Company will be participating in two upcoming conferences:
- 4th Annual Neuroscience Innovation Forum – Norbert Riedel, Ph.D., chief executive officer, will participate in the Pain & Addiction Panel discussion at 11:30 a.m. ET on April 29, 2021; and
- 7th Annual Truist Securities Life Sciences Summit – Aptinyx management will participate in one-on-one meetings with investors throughout the conference on May 4 – 5, 2021.
About Aptinyx
Aptinyx Inc. is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of proprietary synthetic small molecules for the treatment of brain and nervous system disorders. Aptinyx has a platform for discovery of novel compounds that work through a unique mechanism to modulate—rather than block or over-activate—NMDA receptors and enhance synaptic plasticity, the foundation of neural cell communication. The company has three product candidates in clinical development in central nervous system indications, including chronic pain, post-traumatic stress disorder, and cognitive impairment. Aptinyx is also advancing additional compounds from its proprietary discovery platform, which continues to generate a rich and diverse pipeline of small-molecule NMDA receptor modulators with the potential to treat an array of neurologic disorders. For more information, visit www.aptinyx.com.
Source: Aptinyx Inc.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210427005080/en/
FAQ
What is Aptinyx participating in on April 29, 2021?
When is the 7th Annual Truist Securities Life Sciences Summit?
What are the key focus areas of Aptinyx's therapies?
What mechanism do Aptinyx's therapies target?
What is the stock symbol for Aptinyx?
